On October 15th, Lilly announced the establishment of the China Medical Innovation Center in Beijing and plans to set up Lilly Gateway Labs (LGL) to promote clinical research and accelerate drug development.
It is reported that the Lilly China Medical Innovation Center, located in Beijing, is a cutting-edge research center dedicated to improving clinical trial efficiency, supporting drug registration and evaluation, and aiming to accelerate the benefit of innovative drugs to patients. Relying on the profound clinical medical resources in Beijing, the center will integrate advanced technological means and innovative models, optimize real-world data and analysis, and promote the high-quality development of medical research.
At the same time, Lilly announced plans to introduce its innovation incubator (Lilly Gateway Labs, LGL) to China. As a leading innovation platform in the industry, Lilly Innovation Incubator is committed to identifying and supporting high potential biotechnology companies in the early stages of research and development. By integrating Lilly's professional technical resources, LGL will help the next generation of scientific innovation breakthroughs, and this investment marks the company's first expansion of Lilly's innovation incubator beyond the United States.
Daniel Skovronsky, Chief Scientific Officer of Eli Lilly, President of Eli Lilly Research Laboratory, and President of Eli Lilly Immunotherapy, stated that the establishment of Eli Lilly China Medical Innovation Center and Eli Lilly Innovation Incubator in Beijing will further deepen Eli Lilly's century long business layout in China. The new center will empower the exploration of novel clinical research designs to accelerate patients' access to breakthrough therapies. The Lilly Innovation Incubator will provide office space and research strategy guidance for domestic start-up biotechnology companies, helping them develop new generation drugs for patients.